

From (patient name and address)

Date:

Dear Doctor

I am sending this communication to you, so that I can obtain informed consent prior to our joint consideration of the administration of a covid-19 vaccination. I have read the legally binding GMC Guidance on decision making and consent, which MUST be applied prior to any medical intervention including vaccination and I repeat these verbatim here vis:

- a) Recognise risks of harm that you believe anyone in the patient's position would want to know. You'll know these already from your professional knowledge and experience.
- b) The effect of the patient's individual clinical circumstances on the probability of a benefit or harm occurring. If you know the patient's medical history, you'll know some of what you need to share already, but the dialogue could reveal more.
- c) Risks of harm and potential benefits that the patient would consider significant for any reason. These will be revealed during your discussion with the patient about what matters to them.
- d) Any risk of serious harm, however unlikely it is to occur.
- e) Expected harms, including common side effects and what to do if they occur.

[https://www.gmc-uk.org/-/media/documents/gmc-guidance-for-doctors---decision-making-and-consent-english\\_pdf-84191055.pdf](https://www.gmc-uk.org/-/media/documents/gmc-guidance-for-doctors---decision-making-and-consent-english_pdf-84191055.pdf)

All these directions must apply to all the conditions detailed below my signature.

For your information, I do not wish to be vaccinated because I have concerns for my present and future health. However, I am being coerced into vaccination because without such I am unable to work, unable to travel and unable to live my life as a free citizen.

In order that I can proceed either through your assurance that I have received full and proper medical informed consent or that I qualify for vaccine exemption, please can you sign the relevant box below

I, Dr  GMC no.  hereby state that	Dr's signature and date
I have addressed all concerns listed above and detailed below and I am satisfied that this patient has received full informed consent prior to covid-19 vaccination	
I have addressed all concerns listed above and detailed below. I find that I am unable to administer a covid-19 vaccination and I recommend this patient be exempt from such.	

Yours sincerely

Patient name and signature

With Respect to the new COVID-19 vaccinations the Doctor MUST inform the patient of the following and tick the box to indicate such:

Montgomery Judgement & GMC Guidance	Facts	Notes	Discussed
<b>2015 Montgomery Judgement on Informed Consent</b>	The doctor is therefore under a duty to take reasonable care to ensure that the patient is aware of any reasonable alternative or variant treatments.	Vitamin D, 5,000iu daily has proven benefit to prevent and treat Covid-19 Vitamin C, 5 grams daily has proven benefit to prevent and treat Covid-19 Topical antiseptics (such as iodine) are of proven benefit to reduce the loading dose, and hence disease severity, of Covid-19	Yes/No
<b>GMC Guidelines to Doctors</b>	<b>Facts</b>	<b>Notes</b>	<b>Discussed</b>
<b><i>a. Recognised risks of harm that you believe anyone in the patient's position would want to know. You'll know these already from your professional knowledge and experience.</i></b>	<p>Limited short-term safety data: <b>NO</b> long-term safety data available on current CV-19 vaccines, including potential impacts on fertility.</p> <p>mRNA vaccines are a completely novel technology - essentially experimental, with the possibility of unanticipated/unpredictable long- term/late onset health effects</p> <p>Risk of Antibody Dependent Enhancement causing more severe Covid-19 illness on exposure to virus post-vaccination</p>	<p>CV-19 vaccine development accelerated. Vaccine safety testing normally c.10 years. Current CV-19 vaccines trialed for a few months with little/no animal testing. PHASE 3 trials won't complete for 2 years</p> <p><a href="https://www.bmj.com/content/370/bmj.m3096/rr">https://www.bmj.com/content/370/bmj.m3096/rr</a> <a href="https://www.bulatlat.com/2020/08/21/hazards-of-the-covid-19-vaccine/">https://www.bulatlat.com/2020/08/21/hazards-of-the-covid-19-vaccine/</a></p> <p>CV-19 vaccines may sensitize recipients to more severe disease <a href="https://doi.org/10.1111/ijcp.13795">https://doi.org/10.1111/ijcp.13795</a></p> <p>Potential cross-reactivity of vaccine-induced antibodies to virus spike protein, with the placental protein syncytin-1, could cause infertility <a href="https://doctors4covidethics.org/urgent-open-letter-from-doctors-and-scientists-to-the-european-medicines-agency-regarding-covid-19-vaccine-safety-concerns/">https://doctors4covidethics.org/urgent-open-letter-from-doctors-and-scientists-to-the-european-medicines-agency-regarding-covid-19-vaccine-safety-concerns/</a></p>	Yes/No
	There have been reports of some serious side-effects including 2 cases of transverse myelitis and neurological conditions in the Astra Zeneca vaccine trial.	Astra Zeneca Transverse Myelitis report <a href="http://www.nature.com/articles/d41586-020-02594-w">http://www.nature.com/articles/d41586-020-02594-w</a> <a href="https://www.nytimes.com/2020/09/19/health/astrazeneca-vaccine-safety-blueprints.html">https://www.nytimes.com/2020/09/19/health/astrazeneca-vaccine-safety-blueprints.html</a>	Yes/No
	The CDC identified 6 case reports of anaphylaxis following Pfizer-BioNtech vaccine meeting Brighton Collaboration criteria for anaphylaxis.	Anaphylaxis reports: <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/05-COVID-Clark-508.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/05-COVID-Clark-508.pdf</a>	Yes/No
	CDC updated advice on equipment necessary at all vaccination sites to deal with anaphylaxis	Preparations to manage anaphylaxis vaccine recipients:	

		<a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm">https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm</a>	
<b><i>b. The effect of the patient's individual clinical circumstances on the probability of a benefit or harm occurring. If you know the patient's medical history, you'll know some of what you need to share already, but the dialogue could reveal more.</i></b>	<p>It is known that vaccines can switch on allergy and autoimmunity</p> <p>May be contraindicated with pre-existing autoimmune conditions or CFS/ME, or previous vaccine injury/reactions.</p> <p>MHRA 09 December 2020: Any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine. A second dose should not be given to anyone who has experienced anaphylaxis following administration of the first dose of this vaccine</p>	<p>Any patient with a history or strong family history of allergies or autoimmune conditions may choose to refuse a CV-19 vaccine.</p> <p>Doctors working with CFS/ME patients already advise them to avoid vaccination as this may trigger a relapse.</p> <p><a href="https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipient-on-pfizerbiontech-covid-19-vaccine">https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipient-on-pfizerbiontech-covid-19-vaccine</a></p>	Yes/No
<b><i>c. Risks of harm and potential benefits that the patient would consider significant for any reason. These will be revealed during your discussion with the patient about what matters to them.</i></b>	<p>Patient's individual risk from Covid-19 <b>MUST</b> be discussed – IFR &lt;0.05% for &lt;70 years to weigh up against risk from vaccine.</p> <p>Patient expectation of vaccine benefit i.e. reducing risk of severe illness, hospitalisation and preventing infection with and transmission of SARS-Cov-2.</p> <p>Patients <b>MUST</b> be made aware of the full list of vaccine ingredients.</p>	<p>Covid-19 IFR estimate by age (Table 2): <a href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-10-29-COVID19-Report-34.pdf">https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-10-29-COVID19-Report-34.pdf</a></p> <p>Make patient aware that current trials are not designed to show if CV-19 vaccine will reduce their risk of hospitalisation or death or will prevent infection and transmission of virus as may affect risk v benefit profile <a href="https://www.bmj.com/content/371/bmj.m4037">https://www.bmj.com/content/371/bmj.m4037</a></p> <p>Ethical/religious considerations e.g. animal products - vegetarianism/veganism, WI-38 human diploid cells (aborted foetus source) - pro-life/religious belief</p>	Yes/No

<p><b>d. Any risk of serious harm, however unlikely it is to occur.</b></p>	<p>The Doctor <b>MUST</b> consider the significance that the Patient may place on risk of material harm</p> <p>Patient <b>MUST</b> be made aware that the vaccine manufacturers have demanded and been granted immunity from liability for injury or death caused by the vaccines</p>	<p>One example may be if a patient has first-hand knowledge of a relative who has suffered serious harm following vaccination.</p> <p><a href="https://www.gov.uk/government/consultations/distributing-vaccines-and-treatments-for-covid-19-and-flu/outcome/government-response-consultation-on-changes-to-the-human-medicines-regulations-to-support-the-rollout-of-covid-19-vaccines#extending-immunity">https://www.gov.uk/government/consultations/distributing-vaccines-and-treatments-for-covid-19-and-flu/outcome/government-response-consultation-on-changes-to-the-human-medicines-regulations-to-support-the-rollout-of-covid-19-vaccines#extending-immunity</a></p>	<p>Yes/No</p>
<p><b>e. Expected harms, including common side effects and what to do if they occur.</b></p>	<p>Full list of adverse reactions in insert to be shared. Common side-effects include chills, fever, myalgia, fatigue, arthralgia, headache, and pain at the injection site.</p> <p>A reaction to the first dose increases risk of a major reaction to a second dose</p>	<p>Moderna vaccine -100% of high-dose participants report systemic side effects after second dose, some severe</p> <p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022483">https://www.nejm.org/doi/full/10.1056/NEJMoa2022483</a></p> <p>Before a second dose, the patient must be asked about their reaction to the first dose.</p>	<p>Yes/No</p> <p>Yes/No</p>